Literature DB >> 19142478

[Age as an independent prognostic factor in breast cancer].

Willian Simões Clagnan1, Jurandyr Moreira de Andrade, Hélio Humberto Angotti Carrara, Daniel Guimarães Tiezzi, Francisco José Candido dos Reis, Heitor Ricardo Cosiski Marana, Renato Antonio Abrão.   

Abstract

PURPOSE: to compare the epidemiologic and clinical characteristics, and the follow-up of breast cancer in women diagnosed under and over 40 years of age.
METHODS: a retrospective study, case-control type, with analysis of information obtained from medical records of patients attended from January 1994 to June 2004. Cases of intraductal carcinoma and at stage IV were excluded. Three groups were formed: patients under 40 years old at the diagnosis (n=72); patients between 40 and 50 (n=68) and patients over 50 (n=75). Data about age at the moment of diagnosis, lesion largest diameter, clinical stage, type, histological grade, presence of hormonal receptors and state of the lymph nodes were collected and analyzed. The chi2 test was used for qualitative variables. For quantitative variables without normal distribution (such as number of axillary nodes with metastasis and follow-up duration), the Kruskal-Wallis' test was used. For delineating the curves of free-of-disease and global survival, the log-rank test was used.
RESULTS: there was no difference among the groups in the stage distribution, concerning the tumoral differentiation grade or in the distribution of histological types, and in the estrogen receptor and c-erb-B2 expression. Difference was found in the RP expression, which was less frequent in the group of patients under 40, than in the group of patients over 50 (36.2% versus 58.4%) respectively. There was no difference among the groups in the mean tumoral diameter (5.1, 4.7 and 5 cm, respectively). There was also no difference among the groups, concerning the rate of axillary lymph node metastasis (63.9, 46.9 and 50%, respectively). The average follow-up was 54 months for all the groups. Disease recurrence occurred in 22.6% of patients under 40 years old, in 60% of patients between 40 and 50, and in 22.6% of patients over 50, with a significant difference among groups (p<0.0001). Death caused by the disease was higher among patients under 40 (46.9%) than among patients between 40 and 50 (26.9%) and over 50 (22.6%), p=0.0019. The logistic analysis showed that 'age under 40' and the 'presence of more than one metastatic axillary node' were independent death risk factors.
CONCLUSIONS: age under 40 is an independent risk factor for breast cancer. The traditional prognostic indicators, such as stage, tumoral diameter, axillary involvement and presence of hormonal receptors are not associated with the disease evolution.

Entities:  

Mesh:

Year:  2008        PMID: 19142478     DOI: 10.1590/s0100-72032008000200004

Source DB:  PubMed          Journal:  Rev Bras Ginecol Obstet        ISSN: 0100-7203


  3 in total

1.  Histological profile and age at diagnosis of breast and ovarian tumors: A register-based study in Espirito Santo, Brazil.

Authors:  Eldamária DE Vargas Wolfgramm; Camila Fátima Biancardi Gavioli; Mayara Lemos Entringer; Lyvia Neves Rebello Alves; Elaine Stur; Allan Kardec DE Castro Neto; Luciene Lage DA Motta; Fausto Edmundo Lima Pereira; Iuri Drumond Louro
Journal:  Mol Clin Oncol       Date:  2012-11-05

2.  The relationship between NFKB, HER2, ER expression and anthracycline -based neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia.

Authors:  Christian Manginstar; Andi Asadul Islam; Daniel Sampepajung; William Hamdani; Agussalim Bukhari; Salman Ardy Syamsu; Nilam Smaradania; Muhammad Faruk
Journal:  Ann Med Surg (Lond)       Date:  2021-02-10

3.  Retrospective analysis of breast cancer prognosis among young and older women in a Brazilian cohort of 738 patients, 1985-2002.

Authors:  Fabiana De Lima Vazquez; Thiago Buosi Silva; René Aloísio Da Costa Vieira; Allini Mafra Da Costa; Cristovam Scapulatempo; José Humberto Tavares Guerreiro Fregnani; Edmundo Carvalho Mauad; Adhemar Longatto; Kari Juhani Syrjänen
Journal:  Oncol Lett       Date:  2016-11-07       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.